Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Pfizer, Novartis Are Among Overbought Healthcare Stocks: Are They Worth A Look?
01:23pm, Wednesday, 14'th Dec 2022 Benzinga
The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies. Here’s the latest list of major overbought players in this sector, with an RSI
Harrow Health forges agreement to acquire exclusive US rights to blockbuster Novartis eyecare drugs
12:07pm, Wednesday, 14'th Dec 2022
Harrow Health Inc (NASDAQ:HROW) revealed that it has forged a binding agreement for the acquisition of the exclusive US commercial rights to five Food and Drug Administration (FDA) approved ophthalmic
Clovis (CLVS) Files for Bankruptcy Amid Lack of Financial Aid
03:38pm, Monday, 12'th Dec 2022 Zacks Investment Research
Recent regulatory developments force Clovis (CLVS) to file for bankruptcy. The company inks a stalking horse agreement with Novartis for one of its pipeline candidates.
Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to Novartis
02:05pm, Monday, 12'th Dec 2022
Clovis Oncology, maker of ovarian cancer drug Rubraca, has filed for chapter 11 and proposed selling a separate therapy to a Novartis affiliate.
Pharma Stock Roundup: SNY, GSK, PFE Relieved on Zantac Win & Other Updates
02:16pm, Friday, 09'th Dec 2022 Zacks Investment Research
A U.S. district court dismisses thousands of lawsuits involving Zantac, which spells relief for GSK (GSK), Sanofi (SNY) and Pfizer (PFE). Pfizer and AbbVie (ABBV) announce new research collaborations.
Novartis' (NVS) PNH Candidate Achieves Study Objectives
04:31pm, Thursday, 08'th Dec 2022 Zacks Investment Research
Novartis' (NVS) phase III study APPOINT-PNH evaluating investigational oral monotherapy iptacopan in complement-inhibitor-naive (including anti-C5 therapies) adults with PNH meets its primary endpoint
3 Hot Stocks That Could Live Up to Their Lofty Valuations
11:45am, Thursday, 08'th Dec 2022 The Motley Fool
These companies have long runways of growth ahead
Emergent (EBS) OTC Narcan Filing Gets FDA Priority Review Tag
04:08pm, Wednesday, 07'th Dec 2022 Zacks Investment Research
The FDA grants priority review to Emergent's regulatory filing seeking approval for an OTC version of its Narcan nasal spray. A final decision is expected by March 2023-end.
Novartis' (NVS) Pluvicto Meets Goal in 2nd Prostate Cancer Study
03:02pm, Monday, 05'th Dec 2022 Zacks Investment Research
Novartis' (NVS) phase III PSMAfore study evaluating Pluvicto for treating patients with PSMA-positive metastatic castration-resistant prostate cancer meets primary endpoint.
Novartis prostate cancer drug trial meets primary endpoint
06:44am, Monday, 05'th Dec 2022 MarketWatch
The data will be submitted for regulatory approval next year to the U.S. Food and Drug Administration , Novartis said.
Novartis prostate cancer drug trial meets primary endpoint
01:44am, Monday, 05'th Dec 2022
Novartis AG said Monday that a trial to evaluate prostate-cancer drug Pluvicto met its primary endpoint in patients with a specific type of metastatic cancer.
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
11:01am, Friday, 02'nd Dec 2022 Benzinga
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.
Th
10 High-Yield Dividend Aristocrats For A Rolls Royce Retirement
12:00pm, Wednesday, 30'th Nov 2022 Seeking Alpha
The 2022 bear market likely has another 16% to 28% lower to fall before it bottoms in H1 2023. Find out 10 high yield dividend aristocrats for dream retirement.
Incyte (INCY) Outperforms YTD: Will the Momentum Continue?
02:45pm, Friday, 25'th Nov 2022 Zacks Investment Research
Incyte (INCY) outperforms the biotech industry in the year so far and the momentum should continue in 2023 as well.
Novartis (NVS) Set to Advance Malaria Drug Into Phase III
03:24pm, Thursday, 24'th Nov 2022 Zacks Investment Research
Novartis (NVS) plans to advance ganaplacide/lumefantrine into a phase III study for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.
